Medtronic agreed to acquire HeartWare International Inc. on June 27 for approximately $1.1 billion.

In the wake of Theranos voiding two years of reports from its Edison blood testing devices, Walgreens has decided to terminate its partnership in lab testing at more than 40 Walgreens locations in Arizona.

Valeant Pharmaceuticals agreed to pay $54 million to settle a civil lawsuit, Reuters reports. The U.S. Department of Justice (DOJ) announced on June 9 that the agreement between the government and Valeant pertains to allegations against Salix Pharmaceuticals, which Valeant acquired in April 2015.

UnitedHealthcare’s decision to make devices from Medtronic the preferred insulin pump for type 1 diabetics has angered some patients, the Star Tribune reports. UnitedHealthcare told the newspaper that Medtronic’s devices help prevent complications, making them safer than alternatives.

During Medtronic’s investor day on June 6 in New York, the company said it expects to deliver approximately $40 billion in free cash in the next five years.

When Valeant Pharmaceuticals reports its first quarter earnings on June 7, investors and analysts will pay attention to the results, the Wall Street Journal reports. The newspaper wrote that people will be interested to know how Valeant plans on paying down its $32 billion debt load and whether the company can meet its projections of $2.3 billion to $2.4 billion in revenue and $1.18 to $1.43 in adjusted earnings per share.

Saint Michael’s Medical Center Inc. agreed to pay $450,000 to resolve allegations that it submitted claims for performing PCIs, catheterizations and stents on Medicare and Medicaid patients that were medically unnecessary, according to a U.S. Department of Justice news release.

A federal jury in Boston ruled in favor of CardiAQ Valve Technologies and awarded the company $70 million in a lawsuit filed against Neovasc, a former service provider.